CEC Capital Group participates as a lead investor

On September 1, 2020, Thery Pharm (the “Company”), a benchmarking company for specialty Active Pharmaceutical Ingredients (APIs), announced the completion of a Series C financing round of nearly RMB 250 million.

This financing round was jointly led by SND Ventures Group and CEC Capital Group. New investors include Golden Partners Capital, Suzhou Guofa Venture Capital, and Tahoe Venture. Existing shareholder Legend Capital also increased its holdings in the Company.

Thery Pharm is a benchmarking company in the field of domestic specialty APIs and high-end preparations. With this round of financing, the Company will further consolidate its product R&D pipeline, accelerate the development of drugs under research, and enhance its independent R&D capabilities.

Since its establishment in 2010, the Company has focused on the R&D, production and sales of specialty APIs and high-end preparations, and has developed an extensive product pipeline. Its R&D projects cover several areas of the market including anti-tumor, digestion, cardiovascular, cerebrovascular, peptide, and antiviral, among others. Seven preparation products and 14 API products have been approved for marketing, and 11 lines of products have obtained clinical approvals, including several that have obtained EU and US FDA certifications and are industry leading products.

The Company has core technologies for APIs such as crystallization and purification, green synthesis, and complex multi-chiral center synthesis. The Company has built three high-end formulation technology platforms for multi-unit sustained-release pellets, polypeptide oral formulations, and long-acting injections. In December 2019, it was selected as the "2019 Suzhou Unicorn Enterprise of the Year", reflecting the government's affirmation and expectations of the Company's future potential.

As a national high-tech enterprise, Thery Pharm has undertaken 2 national-level projects and has more than 40 approved domestic patents and 6 approved foreign patents. The Company is committed to R&D as its primary focus. Through technology and business model innovation in accordance with international standards, the Company has created a vertically integrated platform covering the entire ecosystem from specialty raw materials to high-end preparations.

About CEC Capital Group’s Future Industry Fund

CEC Capital Group’s Future Industry Fund is the first RMB fund established by CEC Capital Group, a leading investment bank in China. The Future Industry Fund focuses on growth investment opportunities in the areas of health, consumer, and TMT. The fund’s portfolio currently includes investments in China (Miss Fresh, Arrail Dental, and Universal Medical Imaging, among others) as well as in the US (Freenome). The Future Industry Fund currently operates out of offices in Beijing and Shanghai.